Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 7
1993 5
1994 1
1995 3
1996 1
1997 5
1998 14
1999 29
2000 13
2001 22
2002 26
2003 19
2004 24
2005 16
2006 10
2007 17
2008 12
2009 10
2010 3
2011 6
2012 5
2013 11
2014 6
2015 8
2016 5
2017 5
2018 3
2019 4
2020 3
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Eprosartan.
McClellan KJ, Balfour JA. McClellan KJ, et al. Drugs. 1998 May;55(5):713-8; discussion 719-20. doi: 10.2165/00003495-199855050-00011. Drugs. 1998. PMID: 9585867 Review.
Eprosartan is a nonpeptide angiotensin II receptor antagonist which has a high affinity for the AT1 receptor subtype. ...Eprosartan was at least as effective as enalapril 10 to 40 mg/day in a dose-titration study in patients with severe hypertension. ...
Eprosartan is a nonpeptide angiotensin II receptor antagonist which has a high affinity for the AT1 receptor subtype. ...Eprosarta …
Drugs for hypertension.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. Med Lett Drugs Ther. 2020. PMID: 32555118 No abstract available.
Eprosartan: a review of its use in hypertension.
Plosker GL. Plosker GL. Drugs. 2009;69(17):2477-99. doi: 10.2165/11203980-000000000-00000. Drugs. 2009. PMID: 19911859 Review.
Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension. ...Eprosartan was generally well tolerated in clinical trials and had a lower incidence of persistent dry cough than enalapril. ...
Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension. .. …
Eprosartan: a review of its use in the management of hypertension.
Plosker GL, Foster RH. Plosker GL, et al. Drugs. 2000 Jul;60(1):177-201. doi: 10.2165/00003495-200060010-00009. Drugs. 2000. PMID: 10929934 Review.
Eprosartan is a potent and selective angiotensin II subtype 1 receptor antagonist. ...Overall, eprosartan was well tolerated with a similar tolerability profile to that of placebo. ...
Eprosartan is a potent and selective angiotensin II subtype 1 receptor antagonist. ...Overall, eprosartan was well tolerated w …
Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Böhm M, Sachse A. Böhm M, et al. Drug Saf. 2002;25(8):599-611. doi: 10.2165/00002018-200225080-00005. Drug Saf. 2002. PMID: 12113644 Review.
Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile. ...Of these studies, four were controlled with patients receiving a fixed-dose combination, six were long-term, open-label, and another four were controlled studies with hydrochlorot …
Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile. ...Of these studies, four were controlled …
Safety and tolerability of eprosartan.
Gavras I, Gavras H. Gavras I, et al. Pharmacotherapy. 1999 Apr;19(4 Pt 2):102S-107S. doi: 10.1592/phco.19.7.102s.30945. Pharmacotherapy. 1999. PMID: 10213529 Review.
The safety and tolerability of eprosartan were extensively assessed in 17 phase IIb-III studies that included 2709 patients with hypertension. The frequency of adverse events observed with eprosartan was similar to that seen with placebo. Neither the number nor the …
The safety and tolerability of eprosartan were extensively assessed in 17 phase IIb-III studies that included 2709 patients with hype …
Clinical profile of eprosartan.
Puig JG, López MA, Bueso TS, Bernardino JI, Jiménez RT; Grupo MAPA-MADRID Investigators. Puig JG, et al. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. doi: 10.1023/a:1022915220753. Cardiovasc Drugs Ther. 2002. PMID: 12766389 Review.
However, a greater proportion of patients achieved adequate BP control compared with enalapril. When eprosartan is given in combination with hydrochlorothiazide (HCTZ), it provides a significantly greater BP reduction compared with eprosartan alone. ...Further devel …
However, a greater proportion of patients achieved adequate BP control compared with enalapril. When eprosartan is given in combinati …
A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
Blum RA, Kazierad DJ, Tenero DM. Blum RA, et al. Pharmacotherapy. 1999 Apr;19(4 Pt 2):79S-85S. doi: 10.1592/phco.19.7.79s.30948. Pharmacotherapy. 1999. PMID: 10213526 Review.
A series of clinical pharmacology studies was conducted to characterize potential interactions between eprosartan and other commonly prescribed drugs. ...Ranitidine, HCTZ, ketoconazole, and fluconazole had no effect on eprosartan pharmacokinetics. Single or m …
A series of clinical pharmacology studies was conducted to characterize potential interactions between eprosartan and other co …
Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV. Ram CV. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S5-11. doi: 10.1185/030079907X260700. Curr Med Res Opin. 2007. PMID: 18093408 Review.
Of importance to isolated systolic hypertension, trough sitting systolic blood pressure (SBP) is also significantly reduced with eprosartan. In addition, many studies have shown how the benefits of eprosartan go beyond that of blood pressure control alone. ...Clinic …
Of importance to isolated systolic hypertension, trough sitting systolic blood pressure (SBP) is also significantly reduced with eprosart …
Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
Cheng-Lai A. Cheng-Lai A. Heart Dis. 2002 Jan-Feb;4(1):54-9. doi: 10.1097/00132580-200201000-00010. Heart Dis. 2002. PMID: 11975834 Review.
Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. ...The frequency of adverse events observed with eprosartan has been similar to that seen with placebo. In addition, there are no clinicall …
Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. ...The …
294 results